Sun05192019

Robins Global News & Noticias



  • Shipping Advice
    Shipping Advice
  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Trump Pence News
    Trump Pence News
  • Weather Alerts
    Weather Alerts

RobinsPost News Network

+ Larger Font | + Smaller Font

Consumer Daily Reports

Consumer News: FDA approves new generic version of valsartan

PhotoThe Food and Drug Administration (FDA) has approved a new generic version of the blood pressure drug valsartan, which is also sold under the trade name Diovan. Valsartan is a widely used angiotensin II receptor blocker (ARB) that doctors prescribe for high blood pressure and heart failure.

The approval was placed on the FDA fast track after the agency confirmed the presence of an impurity in several lots of the medicine last year. Researchers detected a trace amount of an unexpected impurity -- N-nitrosodimethylamine (NDMA). NDMA has been classified as a probable human carcinogen by the International Agency for Research on Cancer (IARC).

The discovery led to major recalls of existing forms of valsartan, which in turn led to shortages of the drug.

“To address the public health consequences of these shortages, we've prioritized the review of generic applications for these valsartan products,” said FDA Commissioner Scott Gottlieb. “When faced with a drug shortage situation, the FDA employs a number of strategies to help mitigate the effects of the shortage on patients. As part of that work, we look at where we may be able to prioritize review of pending generic applications of the medicine in shortage, or similar products.”

Gottlieb said he is hopeful the approval of the new generic will quickly alleviate the valsartan shortage. Meanwhile, he says the FDA will step up its efforts to keep impurities out of approved prescription drugs.

Suspected human carcinogen

Valsartan began disappearing from pharmacies in the middle of last year after a Chinese company reported the presence of NDEA in several batches of its valsartan API. It was of special concern since NDEA is a suspected human carcinogen.

The FDA began its tests after the Chinese report and resulting recalls. The FDA probe, completed in September, not only found the impurity in the Chinese company's product, but also in Torrent Pharmaceutical’s valsartan 160mg (lot BV47D001) and 320mg (lots BV48D001 and BV48D002) tablets.

The discovery of a potential carcinogen in a prescription drug may well have been a wakeup call for the agency, It says it has conducted a major investigation to address the presence of nitrosamine impurities in certain generic ARB products.

The FDA says it has also worked with companies to move quickly to remove any products with unacceptable impurities from the U.S. market.



Posted: 2019-03-13 14:41:41

Get Full News Story On Consumer Affairs


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.


Print Friendly and PDF Share Embed


Related News Stories From The Web And More

Related Bing News

Consumer News: FDA approves new generic version of valsartan | Consumer Daily Reports | RobinsPost News Network - Newscast

FDA approves new generic version of valsartan

Wed, 13 Mar 2019 07:47:00 GMT

The Food and Drug Administration (FDA) has approved a new generic version of the blood pressure drug valsartan, which is also sold under the trade name Diovan. Valsartan is a widely used angiotensin ...

FDA approves new generic version of oft-recalled blood pressure and heart medication

Wed, 13 Mar 2019 03:50:00 GMT

Here's how the recall process works and what you should do if a medicine you use is recalled. By The FDA approved a new generic version of valsartan, a blood pressure and heart medication drained into ...

FDA approves new valsartan generic to counter shortages of the blood pressure drug

Tue, 12 Mar 2019 16:16:00 GMT

The Food and Drug Administration on Tuesday approved a new generic version of valsartan to alleviate recent shortages of the blood pressure medication following a series of safety recalls. There have ...

FDA approves new generic valsartan to make up for drug shortage

Tue, 12 Mar 2019 13:51:00 GMT

(CNN)The US Food and Drug Administration approved a new generic of valsartan on Tuesday to help relieve the ... The FDA prioritized review of the newly approved generic version of this medicine to ...

FDA approves generic valsartan amid drug shortage

Tue, 12 Mar 2019 12:56:00 GMT

(Reuters) - The U.S. Food and Drug Administration said on Tuesday it had approved a new generic version of blood pressure medicine valsartan, as the agency looks to ease shortages triggered by several ...

Related Bing Web Search

FDA approves generic valsartan amid drug shortage - Reuters

(Tue, 12 Mar 2019 20:34:00 GMT)

The U.S. Food and Drug Administration said on Tuesday it had approved a new generic version of blood pressure medicine valsartan, as the agency looks to ease shortages triggered by several ...

Diovan Prices, Coupons & Savings Tips - GoodRx

(Wed, 15 May 2019 08:12:00 GMT)

Valsartan (Diovan) is a moderately priced drug used to treat high blood pressure.This drug is also used to treat patients with heart failure and patients who have had a heart attack.This drug is more popular than comparable drugs. It is available in brand and generic versions.

We manufacture niche and complex Pharma ... - Natco Pharma

(Thu, 16 May 2019 04:29:00 GMT)

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce the final approval of Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Bosentan tablets in the strengths of 62.5 mg and 125 mg. Bosentan is used for the treatment of patients with pulmonary arterial hypertension.

Generic Drug Guide - Humana

(Wed, 15 May 2019 10:07:00 GMT)

Generic alternatives and generic equivalents to brand-name medications may help patients save money. The U.S. Food and Drug Administration (FDA) states that it ensures the safety and effectiveness of the generic drugs it approves. 1 According to the FDA, a generic drug is identical, or bioequivalent, to a brand-name drug and is "required to have the same active ingredient, strength, dosage ...

Global Novartis News Archive | Novartis

(Fri, 17 May 2019 21:10:00 GMT)

Review recent and past Novartis healthcare news stories, including media releases and featured information.

News and analysis on drug prices from the ... - goodrx.com

(Wed, 15 May 2019 13:06:00 GMT)

If you are taking the popular blood pressure drug, losartan, you may have seen the news reports about contamination. Between November 2018 and April 2019, close to 300 lots of drugs containing losartan were recalled because potentially cancer-causing substances were found in the medications.

Dangerous Drugs & Biologics: Side Effects & FDA Regulation

(Wed, 25 Oct 2017 20:36:00 GMT)

feature black box warnings — the FDA’s strongest warnings— for “disabling and potentially irreversible serious adverse reactions” such as tendinitis and tendon rupture; peripheral neuropathy and central nervous system effects. Drugs in this class include Cipro, Avelox and Levaquin and are reserved for use in patients who have certain conditions that cannot be cured with other ...

List of largest selling pharmaceutical products - Wikipedia

(Thu, 16 May 2019 05:55:00 GMT)

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources.Unsourced material may be challenged and removed. November 2017) (Learn how and when to remove this template message)

Novartis - Wikipedia

(Fri, 17 May 2019 07:56:00 GMT)

Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland.It is one of the largest pharmaceutical companies by both market capitalization and sales. Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec/Glivec), ciclosporin (Neoral/Sandimmun), letrozole ...

Cardiology News & Opinion – theheart.org | Medscape

(Fri, 17 May 2019 05:40:00 GMT)

Cardiology : Welcome to theheart.org | Medscape Cardiology, where you can peruse the latest medical news, commentary from clinician experts, major conference coverage, full-text journal articles ...

Related News Story Videos From Youtube

Mylan expands nationwide recall for blood pressure medication


Related Videos On: Mylan expands nationwide recall for blood pressure medication


FDA expands recall of Valsartan drugs


Related Videos On: FDA expands recall of Valsartan drugs


In 2018 FDA approved highest number of generic drugs ever: Alex Azar


Related Videos On: In 2018 FDA approved highest number of generic drugs ever: Alex Azar


Ex-FDA Inspector Sounds About Overseas Factories Producing Medications For U.S. | NBC Nightly News


Related Videos On: Ex-FDA Inspector Sounds About Overseas Factories Producing Medications For U.S. | NBC Nightly News


Ambien Get FDA's 'Black Box' Label


Related Videos On: Ambien Get FDA's 'Black Box' Label






Blow Us A Whistle

Comments (Whistles) Designed By Disqus




Company Information

Official Content Providers











PRIVACY POLICY

We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
© 2008-2019 RobinsPost (The Bird's Eye View Company) All rights are reserved.
RobinsPost provides links to news sites based on their RSS feeds.
All trademarks, copyrights, videos, photos and logos are owned by news sources.
News stories, videos and live streams are from trusted sources:
Bing News, Google News, NewsApi.org and YouTube Search Results.
ROBINSPOST Is Proudly Made In America.
Where Quality, Safety and Service Comes First.